Close

Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting

Go back to Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
(NYSE: RCUS) Delayed: 18.91 +0.70 (3.84%)
Previous Close $18.21    52 Week High
Open $18.30    52 Week Low
Day High $18.98    P/E N/A 
Day Low $18.18    EPS
Volume 170,914